Month: March 2022

Homology Medicines to Participate in Upcoming Investor Conferences

Written by Customer Service on March 3, 2022. Posted in Public Companies.

BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences:Cowen 42nd Annual Health Care Conference:Corporate Panel Discussion – Gene Editing: March 8 at 12:50 p.m. ETOppenheimer 32nd Annual Healthcare Conference:Fireside Chat: March 16 at 1:20 p.m. ETH.C. Wainwright Gene Therapy and Gene Editing Conference:Available on-demand March 30 at 7:00 a.m. ETThe webcast presentations from the investor conferences will be accessible on Homology’s website in the Investors section, and the webcast replays will be available on the website for 90 days following the presentations. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated...

Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Written by Customer Service on March 3, 2022. Posted in Public Companies.

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in the 32nd Annual Oppenheimer Healthcare Conference, taking place virtually March 15-17, 2022. John Celebi, MBA, president and chief executive officer of Sensei Biotherapeutics, and Erin Colgan, chief financial officer, will participate in a virtual presentation beginning at 10:40 am ET on Tuesday, March 15, 2022. A webcast of the presentation will be available on the Events & Presentations section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. About Sensei BiotherapeuticsSensei Biotherapeutics is a biopharmaceutical...

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

Written by Customer Service on March 3, 2022. Posted in Public Companies.

– Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module1 – Method for expressing stable low levels of a toxic gene – technology deployed in Autolus’ approach for the treatment of solid tumors – Highly restricted IL-12 release increases CAR T activity in an immunocompetent mouse model without systemic toxicity LONDON, March 03, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of an article in BioTechniques describing a novel technology that provides for very low levels of expression of one gene module, while maintaining high levels of expression of other gene modules...

HEXO and Tilray Brands Agree to Create Strategic Alliance Bringing Together Two Canadian Cannabis Leaders

Written by Customer Service on March 3, 2022. Posted in Public Companies.

HEXO to Restructure Balance Sheet, Including Sale of Amended Senior Secured Convertible Notes to Tilray Brands, Significantly Improving Flexibility and Reinvigorating HEXO’s Path Forward Strategy Proposed restructuring of Notes eliminates monthly redemption feature, amends financial covenants, extends maturity and releases US$80M in restricted cash to fund operations and strategic initiatives Both companies expected to realize commercial benefits with production efficiencies and support services of up to C$50M within 24 months to be shared equally between HEXO and Tilray Brands KAOS Capital and partners to provide additional C$180M three-year equity backstop commitment to maintain newly robust balance sheet Joint conference call to discuss announcement at 8:30 a.m. ET today GATINEAU, Quebec, March 03, 2022 (GLOBE NEWSWIRE) — HEXO...

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Written by Customer Service on March 3, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. Jensen brings extensive and diversified experience within global pharmaceutical and medical device companies to Synlogic, spanning analytics, financial management, information systems, and operations. “I am delighted to welcome Michael to Synlogic,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “Michael has an impressive finance and operations background from his roles at multiple biopharma and healthcare companies. This broad experience will be critical as we progress toward late...

ProntoForms Announces Q4 & Fiscal Year 2021 Financial Results Conference Call Date

Written by Customer Service on March 3, 2022. Posted in Public Companies.

OTTAWA, March 03, 2022 (GLOBE NEWSWIRE) — ProntoForms Corporation (TSXV: PFM), the global leader in no-code app development platforms for field teams, today announced that it will report its fourth quarter and fiscal year 2021 earnings for the period ended December 31st, 2021, before market open on Thursday, March 10th, 2022. ProntoForms will hold a conference call on Thursday, March 10th, at 9:00am EST hosted by CEO Alvaro Pombo and CFO Dave Croucher. A question and answer session will follow. Date: Thursday, March 10th, 2022Time: 9:00 AM Eastern Time Participant Dial-in Numbers:Local Toronto – (+1) 647-484-0478Toll Free – (+1) 888-254-3590Conference ID: 8795721 Recording Playback Numbers:Local Toronto– (+1) 647-436-0148Toll Free – (+1) 888-203-1112Passcode: 8795721Expiry Date: March 17th, 2022 at 11:59pm EST A live audio webcast...

SpotLite360 IOT Solutions, Inc. Executes Definitive Agreement to Acquire Majority Interest in E3 Service Group

Written by Customer Service on March 3, 2022. Posted in Mergers And Acquisitions.

DENVER and VANCOUVER, British Columbia, March 03, 2022 (GLOBE NEWSWIRE) — SPOTLITE360 IOT SOLUTIONS, INC. (“SpotLite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) announces that it has entered into a binding definitive agreement with E3 Service Group (“E3”) dated March 2, 2022 under which SpotLite360 will acquire a majority equity interest in E3. Pursuant to the November 15, 2021 announcement of entering into a non-binding Letter of Intent, the Company conducted due diligence, finalized negotiations and documented the framework of an acquisition transaction. The transaction is anticipated to close in early March 2022 and is subject to applicable filings with the Canadian Securities Exchange. E3 has successfully built an award winning design, engineering and implementation practice in the agricultural/cannabis...

Lifetime Brands Acquires S’well®

Written by Customer Service on March 3, 2022. Posted in Mergers And Acquisitions.

GARDEN CITY, N.Y., March 03, 2022 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global provider of kitchenware, tableware and other products used in the home, today announced that it has acquired the business and certain assets of Can’t Live Without It (d/b/a S’well Bottle). Founded in 2010, S’well is a global designer, wholesaler and retailer of reusable, vacuum-insulated products. It is best known for creating the first, reusable hydration fashion accessory. S’well’s products can be purchased through omnichannel retail partners, specialty stores, co-branded partnership opportunities, and its own direct-to-consumer website, www.swell.com. Rob Kay, Lifetime’s Chief Executive Officer, commented, “We are extremely pleased to welcome the S’well brand to our portfolio. S’well originated the category of...

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

Written by Customer Service on March 3, 2022. Posted in Earnings Releases And Operating Results.

Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which excludes the gain on the sale of OTREXUP®. The Company also reported record full-year 2021 revenue of $184.0 million, net income of $46.3 million, or...

The Tile Shop Reports Fourth Quarter and Full-Year 2021 Results

Written by Customer Service on March 3, 2022. Posted in Earnings Releases And Operating Results.

MINNEAPOLIS, March 03, 2022 (GLOBE NEWSWIRE) — Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories, today announced results for its fourth quarter and full-year ended December 31, 2021. Fourth Quarter Summary Net Sales Increased 10.6%Comparable Store Sales Increased 10.3% Gross Margin of 66.1%Net income of $1.8 Million; Adjusted EBITDA of $9.8 MillionDiluted Earnings per Share $0.04Declared and paid a special dividend of $0.65 per share Full-Year 2021 Summary Net Sales Increased 14.0%Comparable Store Sales Increased 13.8% Gross Margin of 68.3%Net income of $14.8 Million; Adjusted EBITDA of $50.3 MillionDiluted Earnings per Share $0.29Opened 1 new store during the year Management Commentary – Cabell Lolmaugh,...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals